Document is current

Article History

Received: 8 September 2025

Accepted: 29 May 2026

First Online: 12 June 2026

Declarations

:

: Ethics Committee’s at the 8 Chinese sites (Beijing Tiantan Hospital, Peking Union Medical College Hospital, Huashan Hospital of Fudan University, Xiangya Hospital, The Second Affiliated Hospital of Soochow University, Xuanwu Hospital, Beijing Hospital, and West China Hospital) approved the protocol and the trial was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice Guidelines. All participants provided written informed consent; the study was registered on June 16, 2022, with Clinicaltrals.gov (NCT05453058).

: Not applicable.

: TF, JW, JW, BT, CL, HC, WM, PC, HS, and LC were study investigators, and they or their institution received fees from Lundbeck for participation. OR has participated in advisory boards and/or provided consultancy for AbbVie, Adamas, Acorda, Addex, AlzProtect, ApoPharma, AstraZeneca, Axovant, Bial, Biogen, Britannia, Buckwang, CereSpir, Clevexel, Denali, INC Research, IPMDS, Lundbeck, Lupin, Merck, MundiPharma, NeurATRIS, NeuroDerm, Novartis, ONO Pharma, Osmotica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Roche, Sanofi, Servier, Sunovion, Theranexus, Takeda, Teva, UCB, Vectura, Watermark Research, XenoPort, XO, Zambon; received grants from Agence Nationale de la Recherche (ANR), CHU de Toulouse, France-Parkinson, INSERM-DHOS Recherche Clinique Translationnelle, MJ Fox Foundation, Programme Hospitalier de Recherche Clinique, European Commission (FP7, H2020), and Cure Parkinson’s. WGM has received consultancy fees from Lundbeck, Takeda, Inhibikase, GE and Koneksa. QZ is employed by Lundbeck (Beijing) Pharmaceutical Consulting Co, Ltd and AB, AR, and DOA are employees of H. Lundbeck A/S.